Scientist Antonio will share with you how trans-resveratrol supplements can keep your brain healthy as you age. The human clinical trial was published in the “Nutrients” journal in March 2020. In this video, he will summarize four important results from this long-term 12-month clinical trial.
The following content is to provide you the insights into the video’s content. To see the charts and figures Dr. Silva mentioned, please watch the above video. Dr. Antonio Silva will share with you a clinical trial published in the studying trans-resveratrol’s capability of enhancing cognitive and cerebrovascular functions.
What is resveratrol?
Resveratrol is a polyphenol that can be found in red wine, grapes, berries, and peanuts. And it has gained a great deal of attention due to its promising benefits towards longevity. Several human clinical trials have confirmed that resveratrol supplementation can also bring exciting health benefits, such as slow down the brain’s age-related cognitive decline.
Cognitive decline: Age-related cognitive decline is an increasing problem in our modern society. Deficits in cerebral microcirculation are presented as one of the causes of this terrible health condition.
Summarize The Clinical Trial
Here, we present the results of a randomized, placebo-controlled human clinical trial aiming to investigate sustained cerebrovascular and cognitive benefits of trans-resveratrol in postmenopausal women. In this study, 129 women aged 45 to 85 were randomized to take a placebo or 75 mg trans-resveratrol in a capsule twice daily for 12 months. Effects on cognition, cerebral blood flow, cerebrovascular responsiveness, and cardio-metabolic markers (blood pressure, diabetes markers, and fasting Lipids) were assessed. Each resveratrol capsule contained 75 mg of synthetic trans-resveratrol with purity higher than 98%.
Resveratrol without being mixed with fat:
I know there is an increasing trend that people tend to take resveratrol supplements by mixing it with fat such as yogurt, however, in this clinical trial, the resveratrol administration was by CAPSULE FORM only.
The important findings:
As you can see in Table 2, it listed all of the participant baseline characteristics including age, years of postmenopausal, BMI, blood pressure, and so on. 146 women were enrolled and randomized into placebo and (73) resveratrol groups. The participants were chosen to have no differences between the placebo or trans-resveratrol groups for all the parameters in question.
The results, can be divided into four parts:
Third, as for the cerebrovascular function in hypercapnia, even though Cerebrovascular Responsiveness (CVR) to hypercapnia was unaffected by resveratrol supplementation after 12 months, a decline in neurovascular coupling capacity was attenuated by resveratrol as you can see in table 4. As you may know, hypercapnia is a buildup of carbon dioxide in your bloodstream. To induce hypercapnia, participants breathed in the gas mixture of 95% oxygen, 5% carbon dioxide for 180 seconds, followed by the measurements.
Overall neurovascular coupling capacity, especially in response to tests of cognitive flexibility, was improved as shown in Figure 4.
Fourth, Cardio-metabolic Markers: No significant differences were observed in cardio-metabolic markers between placebo and resveratrol. However, it was found that there is a correlation between the reductions in fasting blood glucose and the improvements in overall neurovascular coupling capacity with resveratrol supplementation as you can see in Figure 5.
